ClinicalTrials.gg
CompletedNCT00463788BALI-1Updated Feb 13, 2014Results posted

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

A Phase 2 interventional study of cetuximab, cisplatin and cisplatin in Breast Neoplasm, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 46 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 11 studies testing cetuximab in Breast Neoplasms — none open to participants now, 2 under way, none of them phase 3. Cetuximab · Breast Neoplasms.

Enrollment
Largest of 11
181 · median 37
Started
2007
the only one that year
Phase 2
8 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
Merck KGaA, Darmstadt, Germany

Among the 11 studies testing cetuximab in Breast Neoplasms, this one has the largest enrollment, is the only one that started in 2007, is one of 8 in phase 2, and was the 5th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 11 studies testing cetuximab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing cetuximab in Breast Neoplasms as a file.
02

Study summary

The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab and cisplatin was above a pre-specified threshold of 0.2 in the treatment of "triple negative" metastatic breast cancer.

The secondary objective of this study is to compare the differences between the two treatment groups using the following criteria : Progression-Free Survival (PFS) Time, Overall Survival (OS), Time to Response (TTR) and Safety.

03

Conditions studied

  • Breast Neoplasm

Keywords

  • cancer
  • breast
  • metastatic
  • triple negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of breast cancer (Stage IV)
  • Estrogen Receptor [ER] negative, PgR negative and less than 3+ expression by immunohistochemistry (IHC)
  • No more than 1 prior chemotherapy received for treating this metastatic breast cancer
  • No more than 1 prior anthracycline and/or taxane regimen (either or metastatic setting)
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Prior platinum agent
  • Prior mitomycin
  • Known history of
  • Other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    cisplatin and cetuximab

    Drug: cetuximab, cisplatin

  • Active comparator
    cisplatin

    Drug: cisplatin

Interventions

  • Drugcetuximab, cisplatin

    Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion. Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles. Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent.

  • Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles. Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles. Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).

    Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009

Secondary outcomes

  1. Progression-Free Survival (PFS) Time

    The PFS was defined as the duration from randomization until radiological progression according to investigator (based on RECIST) or death due to any cause. Only deaths within 85 days of last tumor assessment were considered. Participants without event were censored on the date of last tumor assessment.

    Time frame: Time from randomization to disease progression, death or last tumour assessment, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009

  2. Overall Survival (OS) Time

    The OS time was defined as the time from randomization to death. Participants without event were censored at the last date known to be alive or at the clinical cut-off date, whatever was earlier.

    Time frame: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 20 June 2007, until cut-off date, 05 April 2010

  3. Time to Response (TTR)

    The TTR was determined for participants whose confirmed BOR (based on RECIST) was either a CR or a PR . It was defined as the time from the first dose study treatment until the date of the first assessment of confirmed CR or PR.

    Time frame: Time from the first dose of study treatment (cetuximab or cisplatin) to first assessment of CR or PR, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009

  4. Safety- Number of Participants Experiencing Any Adverse Event (AE)

    Number of participants experiencing any AE. AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications.

    Time frame: Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010

07

Results

Posted Oct 10, 2012
Limitations and caveats
Participants were randomized to 2 groups in a 2:1 ratio.

Participant flow

Participant flow — Overall Study
MilestoneCisplatin and CetuximabCisplatin
Started11558
Treated11457
Completed64
Not completed10954
Withdrew: Progressive disease8642
Withdrew: Adverse event62
Withdrew: Withdrawal by subject62
Withdrew: Death43
Withdrew: Symptomatic deterioration23
Withdrew: Lost to follow-up10
Withdrew: Protocol violation01
Withdrew: Other30
Withdrew: Randomized but not treated11

Outcome measures

PrimaryBest Overall Response (BOR)

Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).

Time frame:
Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Reported as:
Number · percentage of participants
Best Overall Response (BOR)
percentage of participantsCisplatin and CetuximabCisplatin
Best Overall Response (BOR)20.0 (13.1 to 28.5)10.3 (3.9 to 21.2)
Statistical analysis
  • Cisplatin and Cetuximab vs Cisplatin · Cochran-Mantel-Haenszel · p = 0.1109 · Odds ratio (or): 2.126 · 95% CI 0.809 to 5.591Randomization strata: first- or second line according to Interactive Voice Response System (IVRS).
SecondaryProgression-Free Survival (PFS) Time

The PFS was defined as the duration from randomization until radiological progression according to investigator (based on RECIST) or death due to any cause. Only deaths within 85 days of last tumor assessment were considered. Participants without event were censored on the date of last tumor assessment.

Time frame:
Time from randomization to disease progression, death or last tumour assessment, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Reported as:
Median · months
Progression-Free Survival (PFS) Time
monthsCisplatin and CetuximabCisplatin
Progression-Free Survival (PFS) Time3.7 (2.8 to 4.3)1.5 (1.4 to 2.8)
Statistical analysis
  • Cisplatin and Cetuximab vs Cisplatin · Log Rank · p = 0.0324 · Hazard ratio (hr): 0.675 · 95% CI 0.470 to 0.969
SecondaryOverall Survival (OS) Time

The OS time was defined as the time from randomization to death. Participants without event were censored at the last date known to be alive or at the clinical cut-off date, whatever was earlier.

Time frame:
Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 20 June 2007, until cut-off date, 05 April 2010
Reported as:
Median · months
Overall Survival (OS) Time
monthsCisplatin and CetuximabCisplatin
Overall Survival (OS) Time12.9 (9.6 to 15.6)9.4 (6.7 to 14.2)
Statistical analysis
  • Cisplatin and Cetuximab vs Cisplatin · Log Rank · p = 0.3121 · Hazard ratio (hr): 0.821 · 95% CI 0.561 to 1.204
SecondaryTime to Response (TTR)

The TTR was determined for participants whose confirmed BOR (based on RECIST) was either a CR or a PR . It was defined as the time from the first dose study treatment until the date of the first assessment of confirmed CR or PR.

Time frame:
Time from the first dose of study treatment (cetuximab or cisplatin) to first assessment of CR or PR, reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009
Reported as:
Median · months
Time to Response (TTR)
monthsCisplatin and CetuximabCisplatin
Time to Response (TTR)1.4 (1.3 to 1.4)1.3 (1.2 to 1.4)
Statistical analysis
  • Cisplatin and Cetuximab vs Cisplatin · Log Rank · p = 0.5993 · Hazard ratio (hr): 0.754 · 95% CI 0.262 to 2.170
SecondarySafety- Number of Participants Experiencing Any Adverse Event (AE)

Number of participants experiencing any AE. AEs: Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications.

Time frame:
Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010
Reported as:
Number · participants
Safety- Number of Participants Experiencing Any Adverse Event (AE)
participantsCisplatin and CetuximabCisplatin
Safety- Number of Participants Experiencing Any Adverse Event (AE)11457

Adverse events

Collected over Time from first dose up to 30 days after last dose of study treatment, reported between day of first dose of study treatment, 20 June 2007, until cut-off date 05 April 2010. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cisplatin and Cetuximab—41/114 (36%)112/114 (98.2%)
Cisplatin—13/57 (22.8%)55/57 (96.5%)
Cisplatin Alone Switched to Cetuximab—6/31 (19.4%)28/31 (90.3%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventCisplatin and CetuximabCisplatinCisplatin Alone Switched to Cetuximab
General Physical Health DeteriorationGeneral disorders4/1141/572/31
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders4/1140/572/31
DyspnoaeRespiratory, thoracic and mediastinal disorders6/1141/570/31
PyrexiaGeneral disorders4/1142/571/31
Septic ShockInfections and infestations1/1140/571/31
Femur FractureInjury, poisoning and procedural complications0/1140/571/31
Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1140/571/31
AnaemiaBlood and lymphatic system disorders3/1140/570/31
DiarrhoeaGastrointestinal disorders3/1140/570/31
FatigueGeneral disorders3/1140/570/31
Most frequent other events
Showing 10 of 56
Most frequent other events
EventCisplatin and CetuximabCisplatinCisplatin Alone Switched to Cetuximab
NauseaGastrointestinal disorders73/11437/578/31
VomitingGastrointestinal disorders43/11437/577/31
FatigueGeneral disorders56/11420/576/31
RashSkin and subcutaneous tissue disorders56/1141/575/31
Decreased AppetiteMetabolism and nutrition disorders40/1148/574/31
Dermatitis AcneiformSkin and subcutaneous tissue disorders23/1140/579/31
NeutropeniaBlood and lymphatic system disorders33/11410/573/31
ConstipationGastrointestinal disorders27/11416/575/31
Dry SkinSkin and subcutaneous tissue disorders29/1141/572/31
AstheniaGeneral disorders26/11414/573/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cisplatin and CetuximabCisplatinTotal
Mean52.9 ± 12.5351.7 ± 10.6752.5 ± 11.92
Age, Customized
Age, Customized(participants)Cisplatin and CetuximabCisplatinTotal
< 65 years9351144
>= 65 years22729
Sex: Female, Male
Sex: Female, Male(Participants)Cisplatin and CetuximabCisplatinTotal
Female11558173
Male000
Naturally post menopausal participants
Naturally post menopausal participants(participants)Cisplatin and CetuximabCisplatinTotal
Yes6436100
No512273
Duration of breast cancer from primary tumor diagnosis to informed consent
Duration of breast cancer from primary tumor diagnosis to informed consent(months)Cisplatin and CetuximabCisplatinTotal
Median19.2 (0.0 to 350.0)17.3 (0.0 to 199.0)18.7 (0.0 to 350.0)
Participants categorized by site of metastasis
Participants categorized by site of metastasis(participants)Cisplatin and CetuximabCisplatinTotal
Lung642690
Lymph nodes (by medical review)492271
Bone372057
Liver361753
Skin20828
Other15823
Duration of metastatic breast cancer from metastasis to informed consent
Duration of metastatic breast cancer from metastasis to informed consent(months)Cisplatin and CetuximabCisplatinTotal
Median0.9 (0.0 to 56.0)0.8 (0.0 to 41.0)0.9 (0.0 to 56.0)
Duration from initial breast cancer diagnosis to date of metastasis
Duration from initial breast cancer diagnosis to date of metastasis(months)Cisplatin and CetuximabCisplatinTotal
Median15.7 (0.0 to 349.0)15.4 (-4.0 to 199.0)15.5 (-4.0 to 349.0)
08

Study locations

46 sites
  • Research Site
    Campbelltown, New South Wales, Australia
  • Research Site
    Liverpool, New South Wales, Australia
  • Research Site
    Wollongong, New South Wales, Australia
  • Research Site
    Malvern, Victoria, Australia
  • Research Site
    Perth, Western Australia, Australia
  • Research Site
    Bludesch-Gais, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Brussels, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Liège, Belgium
  • Research Site
    Namur, Belgium
  • Research Site
    Wilrijk, Belgium
  • Research Site
    Frankfurt am Main, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Kiel, Germany
  • Research Site
    Köln, Germany
  • Research Site
    München, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Dublin, Ireland
  • Research Site
    Beer Sheba, Israel
  • Research Site
    Haifa, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Kefar Sava, Israel
  • Research Site
    Petah Tikva, Israel
  • Research Site
    Rehovot, Israel
  • Research Site
    Tel Aviv, Israel
  • Research Site
    Tel Hashomer, Israel
  • Research Site
    Genova, Italy
  • Research Site
    Modena, Italy
  • Research Site
    Christchurch, New Zealand
  • Research Site
    Wellington, New Zealand
  • Research Site
    Coimbra, Portugal
  • Research Site
    Lisboa, Portugal
  • Research Site
    Porto, Portugal
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Murcia, Spain
  • Research Site
    Palma de Mallorca, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Zaragoza, Spain
  • Research Site
    Cardiff, United Kingdom
  • Research Site
    Guildford, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom
09

References and documents

Publications

  • Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy. 2011;57(6):468-87. doi: 10.1159/000334093. Epub 2012 Jan 10. PubMed 22248721 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2007
First posted
Apr 20, 2007
Start
Jun 2007
Primary completionActual
Jul 2009
CompletionActual
Feb 2011
Results first posted
Oct 10, 2012
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00463788
Responsible party
Sponsor
First posted
Apr 20, 2007
Start date
Jun 2007
Primary completion
Jul 2009
Completion
Feb 2011
Results posted
Oct 10, 2012
Last update
Feb 13, 2014

Study contacts

José Baselga, Prof.
principal investigator · General Hospital, Boston, Massachusetts, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin

Start the discussion